Background And Objective: Controversy exists regarding which individuals will benefit most from commencement of diabetes technologies such as continuous subcutaneous insulin infusion (CSII) or continuous glucose monitoring systems (CGMS), such as 'real-time' sensor-augmented pumping (SAP). Because higher usage correlates with haemoglobin A1c (HbA1c) achieved, we aimed to predict future usage of technologies using a questionnaire-based tool.
Subjects: The tool was distributed to two groups of youth with type 1 diabetes; group A (n = 50; mean age 12 ± 2.5 yr) which subsequently commenced 'real-time' CGMS and group B (n = 47; mean age 13 ± 3 yr) which commenced CSII utilisation.
Methods: For the CGMS group, recommended usage was ≥5 days (70%) per week [≥70% = high usage (HU); <70% = low usage (LU)], assessed at 3 months. In the CSII group, HU was quantified as entering ≥5 blood sugars per day to the pump and LU as <5 blood sugars per day, at 6 months from initiation. Binary logistic regression with forward stepwise conditional was used to utilise tool scales and calculate an applied formula.
Results: Of the CGMS group, using gender, baseline HbA1c, and two subscales of the tool generated a formula which predicted both high and low usage with 92% accuracy. Twelve (24%) showed HU vs. 38 who exhibited LU at 3 months. Of the CSII group, 32 (68%) exhibited HU vs. 15 who exhibited LU at 6 months. Four tool items plus gender predicted HU/LU with 95% accuracy.
Conclusions: This pilot study resulted in successful prediction of individuals who will and those who will not go on to show recommended usage of CSII and CGMS.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pedi.12253 | DOI Listing |
Background: Phase 3 randomized clinical trials within Alzheimer's Disease (AD) typically last over 18 months. Post-baseline participants can use additional treatment for Alzheimer's disease, potentially impacting the cognitive ability as evaluated by the primary endpoint. Consequently, this could overestimate or underestimate the treatment effect, depending on the distribution of usage between treatment arms.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE) Rostock/Greifswald, Rostock, Germany.
Background: Using artificial intelligence approaches enable automated assessment and analysis of speech biomarkers for Alzheimer's disease, for example using chatbot technology. However, current chatbots often are unsuitable for people with cognitive impairment. Here, we implemented a user-centred-design approach to evaluate and improve usability of a chatbot system for automated speech assessments for people with preclinical, prodromal and early dementia.
View Article and Find Full Text PDFAnaesthesia
January 2025
Consultant, Department of Peri-operative Medicine, University College London Hospitals NHS Trust, London, UK.
Introduction: This consensus statement gives practical advice for the safe management of patients with harmful alcohol intake undergoing elective and emergency surgery. The wide spectrum of alcohol-related organ dysfunction observed in this cohort of patients may have a profound impact on care, and the additional effects of alcohol withdrawal may further exacerbate postoperative morbidity and mortality.
Methods: A working party was assembled based on clinical and/or academic expertise in the area.
J Pediatr Nurs
January 2025
University of Newcastle, Australia; Centre for Transformative Nursing, Midwifery, and Health Research: A JBI Centre of Excellence, Australia.
Objective: This review aims to investigate parents' preference for and use of Ibuprofen and Paracetamol in managing and treating children's fevers as well as the factors influencing their decision-making and practices.
Introduction: Parents globally face concern over managing children's fever, seeking relief while ensuring safety, often relying on accessible medications like Paracetamol and Ibuprofen.
Inclusion Criteria: The review included quantitative studies involving parents and caregivers managing fever in children aged 0-17 years.
Arch Dermatol Res
January 2025
Department of Dermatology, Massachusetts General Hospital, 50 Staniford Street, Suite 200, Boston, MA, 02114, USA.
Prior studies have highlighted significant challenges in the readability of patient educational materials in dermatology, which may represent a barrier to optimal treatment outcomes. As newer Janus kinase inhibitors (JAKi) gain FDA approval and are integrated into treatment regimens, it is crucial for patients to understand their usage, risks, and benefits. We evaluated the readability of FDA-approved JAKi medication guides to see if lessons from prior readability studies have been incorporated into these newer materials.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!